IP Library Granted Patent US 11,433,037
Granted Patent B2
US 11,433,037 · App. 15/641,448 · Granted Sep 6, 2022

Oral dosage form containing a fast release exterior coating

Inventor: Christopher Joseph Pulford (Lincoln, NE)
Assignee: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
A61K31/167A61K9/0053A61K9/2054A61K9/2826A61K9/2866A61K9/2886A61K31/137A61K31/138A61K31/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,037
App. No.
15/641,448
Granted
Sep 6, 2022
Kind
B2
Abstract

Aspects of the present invention are directed to an oral dosage form comprising a core containing one more active ingredients and a fast-release exterior coating. The fast release exterior coating includes a water soluble polymer; a saccharide or sugar alcohol, or a combination thereof, and a flavoring. The flavoring may be a warming sensate that is released in the oral cavity of the user after inserting the dosage form in his or her mouth.

Claims (45)

1. A coated oral dosage form that provides a sensorial experience in the oral cavity of the user, comprising:

a core comprising between about 300 mg and about 400 mg acetaminophen, between about 5 mg and about 15 mg dextromethorphan, and between about 2.5 mg and about 7.5 mg phenylephrine;

a fast-release exterior coating comprising: between about 2 mg and about 6 mg hydroxypropylmethylcellulose and polyethylene glycol, between about 3 mg and about 5 mg maltodextrin; and between about 0.5 mg and about 2.5 mg warming sensate; and

an intermediate coating comprising between about 10 mg and about 20 mg hydroxypropylmethylcellulose and polyethylene glycol.

2. The coated oral dosage form of claim 1 , wherein the flavoring further comprises a flavor selected from the group consisting of menthol, peppermint, wintergreen, sweet mint, spearmint, vanillin, chocolate, coffee, cinnamon, clove, tobacco, citrus and fruit flavors or mixtures thereof.

3. The coated oral dosage form of claim 1 , wherein the fast release exterior coating has a thickness of between about 100 μm and about 100 μm.

4. The coated oral dosage form of claim 3 , wherein the fast release exterior coating has a thickness of between about 40 μm and about 80 μm.

5. The coated oral dosage form of claim 1 , wherein the fast release exterior coating has a weight of between about 0.5% (w/w) and about 20% (w/w) of the oral dosage form.

6. The coated oral dosage form of claim 1 , wherein the core is a caplet.

7. The coated oral dosage form of claim 1 , wherein the intermediate coating has a thickness of between about 10 μm and about 100 μm.

8. The coated oral dosage form of claim 1 , wherein the coating extends evenly around the entire exterior surface of the oral dosage form.

9. The coated oral dosage form of claim 1 , wherein the intermediate coating has a thickness of between about 50 μm and about 70 μm.

10. The coated oral dosage form of claim 7 , wherein the intermediate coating has a thickness of between about 50 μm and about 70 μm.

11. The coated oral dosage form of claim 1 comprising dextromethorphan as dextromethorphan bromide in an amount of 10 mg and phenylephrine as phenylephrine hydrochloride in an amount of 5 mg.

12. A method of treating the symptoms of cold and/or flu, and/or allergies comprising administering to a human subject in need thereof a coated oral dosage form as described in claim 1 .

13. A coated oral dosage form that provides a sensorial experience in the oral cavity of the user, comprising:

a core comprising between about 300 and about 400 mg acetaminophen, between about 10 mg and about 15 mg diphenhydramine, and between about 2.5 mg and about 7.5 mg phenylephrine;

a fast-release exterior coating comprising between about 2 mg and about 6 mg hydroxypropylmethylcellulose; between about 3 mg and about 5 mg maltodextrin; and

between about 0.5 mg and about 2.5 mg of a warming sensate; and

an intermediate coating comprising between about 10 mg and about 20 mg hydroxypropylmethylcellulose.

14. The coated oral dosage form of claim 13 comprising diphenhydramine as diphenhydramine hydrochloride in an amount of 12.5 mg and phenylephrine as phenylephrine hydrochloride in an amount of 5 mg.

15. The coated oral dosage form of claim 13 , wherein the flavoring further comprises a flavor selected from the group consisting of menthol, peppermint, wintergreen, sweet mint, spearmint, vanillin, chocolate, coffee, cinnamon, clove, tobacco, citrus and fruit flavors or mixtures thereof.

16. The coated oral dosage form of claim 13 , wherein the fast release exterior coating has a thickness of between about 10 μm and about 100 μm.

17. The coated oral dosage form of claim 16 , wherein the fast-release exterior coating has a thickness between about 40 μm and about 80 μm.

18. The coated oral dosage form of claim 13 , wherein the fast release exterior coating has a weight of between about 0.5% (w/w) and about 20% (w/w) of the oral dosage form.

19. The coated oral dosage form of claim 13 , wherein the intermediate coating has a thickness of between about 10 μm and about 100 μm.

20. The coated oral dosage form of claim 19 , wherein the intermediate coating has a thickness of between about 50 μm and about 70 μm.

21. The coated oral dosage form of claim 13 , wherein the fast release exterior coating extends evenly around the entire exterior surface of the oral dosage form.

22. The coated oral dosage form of claim 13 , wherein the core is a caplet.

23. A method of treating the symptoms of cold and/or flu, and/or allergies, comprising administering to a human subject in need thereof a coated oral dosage form as described in claim 13 .

24. A coated oral dosage form that provides a sensorial experience in the oral cavity of the user, comprising:

a core comprising between about 300 mg and about 400 mg acetaminophen, between about 5 mg and about 15 mg dextromethorphan, and between about 2.5 mg and about 7.5 mg phenylephrine;

a fast-release exterior coating comprising: between about 2 mg and about 6 mg hydroxypropylmethylcellulose, between about 3 mg and about 5 mg maltodextrin; and

between about 0.5 mg and about 2.5 mg warming sensate; and.

an intermediate coating comprising between about 10 mg and about 20 mg hydroxypropylmethylcellulose.

25. The coated oral dosage form of claim 24 comprising dextromethorphan as dextromethorphan bromide in an amount of 10 mg and phenylephrine as phenylephrine hydrochloride in an amount of 5 mg.

26. The coated oral dosage form of claim 24 , wherein the fast release exterior coating has a thickness of between about 10 μm and about 100 μm.

27. The coated oral dosage form of claim 24 , wherein the fast release exterior coating has a weight of between about 0.5% (w/w) and about 20% (w/w) of the oral dosage form.

28. A coated oral dosage form that provides a sensorial experience in the oral cavity of the user, comprising:

a core comprising between about 300 and about 400 mg acetaminophen, between about 10 mg and about 15 mg diphenhydramine, and between about 2.5 mg and about 7.5 mg phenylephrine;

a fast-release exterior coating comprising between about 2 mg and about 6 mg hydroxypropylmethylcellulose and polyethylene glycol; between about 3 mg and about 5 mg maltodextrin; and between about 0.5 mg and about 2.5 mg of a warming sensate; and

an intermediate coating comprising between about 10 mg and about 20 mg hydroxypropylmethylcellulose and polyethylene glycol.

29. The coated oral dosage form of claim 28 comprising diphenhydramine as diphenhydramine hydrochloride in an amount of 12.5 mg and phenylephrine as phenylephrine hydrochloride in an amount of 5 mg.

30. The coated oral dosage form of claim 28 , wherein the intermediate coating has a thickness of between about 10 μm and about 100 μm.

31. The coated oral dosage form of claim 28 , wherein the fast release exterior coating has a weight of between about 0.5% (w/w) and about 20% (w/w) of the oral dosage form.

Assignments (3)
CHANGE OF NAME Recorded Mar 1, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066713/0558 →
CHANGE OF NAME Recorded Feb 28, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066701/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2017
From: PULFORD, CHRISTOPHER JOSEPH
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 042969/0546 →
Continuity (2)
Provisional Application 62358223 · Jul 5, 2016
Related Publication 20180008562A1 · Jan 11, 2018